Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|May 15, 2019||2/1/2019||Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis||Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis||Sarcoidosis, Pulmonary;Sarcoidosis Lung;Sarcoidosis||Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension||Oregon Health and Science University||Pfizer||Recruiting||18 Years||89 Years||All||5||Phase 1||United States|
|2||JPRN-UMIN000013831||2014/04/30||30/04/2014||Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation||Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.||inhaled ciclesonide (400maicrogram, twice daily, for three months)||Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan||NULL||Recruiting||20years-old||80years-old||Male and Female||40||Not selected||Japan|
|3||ChiCTR-IOR-15005953||2012-01-01||2015-01-11||The effects of corticosteroid treatment on asymptomatic sarcoidosis||The effects of corticosteroid treatment on asymptomatic sarcoidosis||Sarcoidosis||Corticosteroid-treated group :prednisolone ;Placebo:Placebo;||The First Affiliated Hospital, Guangzhou Medical University||NULL||Completed||18||76||Both||Corticosteroid-treated group :64;Placebo:63;||NULL|
|4||JPRN-UMIN000006533||2010/04/01||30/10/2011||Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects||sarcoidosis||All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations.|
Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment.
Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later.
Cardiac sarcoidosis with steroid treatment.
Cardiac sarcoidosis without steroid treatment.
arcoidosis without cardiac involvement who will have steroid treatement.
Sarcoidosis without cardiac involvement who will not have steroid treatement.
|Hokkaido University Graduate School of Medicine||,NULL||Recruiting||Not applicable||Not applicable||Male and Female||50||Not applicable||Japan|
|September 2009||9/6/2009||Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis||Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE||Sarcoid-associated Uveitis;Ocular Sarcoidosis;Macular Edema||Drug: Methotrexate;Drug: Placebo||Assistance Publique - Hôpitaux de Paris||NULL||Terminated||18 Years||N/A||Both||7||Phase 4||France|